ClinicalTrials.gg
RecruitingNCT07546253Updated Oct 16, 2026

Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy

An observational study in Drug Resistant Epilepsy and Refractory Epilepsy, sponsored by NeuroOne Medical Technologies Corporation. Recruiting at 3 sites in United States. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by NeuroOne Medical Technologies Corporation · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 16, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
100
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Started
2026
with 6 others
Observational
7 of 78
2 open now
Primary completion
2028-07
later than 22 of 33 live
Registered
72nd of 78
by date

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is one of 7 that started in 2026, is one of 7 observational ones, reaches primary completion later than 22 of the 33 other live ones, and was the 72nd registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System. The study focuses on patients with refractory epilepsy who undergo, or are being considered for, sEEG-guided RF ablation using the OneRF Ablation System, as part of routine seizure diagnosis and treatment.

Read the detailed description

Stereoelectroencephalography (SEEG) -guided radiofrequency (RF) ablation is a minimally invasive procedure that uses thin electrodes already placed in the brain for seizure diagnosis to deliver targeted heat to destroy brain tissue associated with epileptic seizures.

The OneRF Ablation System is a device cleared by the FDA in 2023 for this treatment. Since receiving FDA clearance, the OneRF Ablation System has been used in ablation procedures in patients with seizures at multiple hospitals. Early published clinical data show a meaningful decrease in seizure burden (1). One of the key features of the device is the ability to monitor and control temperature throughout the treatment. While the advantages of real-time temperature monitoring and control are increasingly being recognized, additional clinical information would be beneficial to understand the full impact of this technology on patient outcomes.

This study is a prospective and retrospective, multicenter, observational registry. The study will take place at up to 10 sites across the United States and is expected to enroll up to 100 participants, including both adults and children. The goal of the registry is to evaluate clinical outcomes and device performance of the OneRF Ablation System.

The study will include data collection from patients with drug resistant epilepsy who are undergoing sEEG evaluation for seizure diagnosis and treatment, and:

  • Have already had an ablation procedure with the OneRF Ablation System, or
  • Are being considered for treatment with the OneRF Ablation System as part of their clinical seizure evaluation.

Data will be collected from patients before and throughout routine follow-up visits for up to one year after the RF ablation procedure. The study will look at seizure control, quality of life, adverse events, how the procedure is performed, and factors that may predict which patients benefit most.

Taking part in this registry does not change a patient's medical care. The study only collects information from treatments and follow-up visits that are already part of routine practice care for seizure management.

03

Conditions studied

  • Drug Resistant Epilepsy
  • Refractory Epilepsy

Keywords

  • radiofrequency ablation
  • sEEG
  • epilepsy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with drug resistant epilepsy (DRE)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with drug resistant epilepsy (DRE)
  2. Patients who have received or will receive EVO® sEEG-RF implants
  3. Patients who have undergone or may undergo an RF ablation procedure using the OneRF Ablation System.
  4. Patient, or legal guardian, understands study procedures and voluntarily signs in accordance with institutional policies. In the event that the patient is under the age of 18, the patient may also be required (per IRB) to sign an assent affirming their agreement to participate.

Exclusion criteria

Exclusion Criteria:

1. Any condition that, in the judgement of the clinician, would make the participant inappropriate for registry participation

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
100 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Patients who have received or will receive an RF ablation procedure using the OneRF Ablation System

    This registry collects both retrospective data from patients diagnosed with drug resistant epilepsy (DRE) who previously underwent a RF ablation procedure and prospective data from DRE patients who are considered for a RF ablation procedure using the OneRF Ablation System.

    Other: Participants are not assigned an intervention as part of the study.

Interventions

  • OtherParticipants are not assigned an intervention as part of the study.

    For observational studies, participants are not assigned an intervention as part of the study.

06

What researchers measure

Primary outcomes

  1. Evaluate seizure outcomes

    Percentage of seizure-free patients and responders (seizure reduction \>50%) at longitudinal time points

    Time frame: baseline to up to one (1) year

  2. Evaluate changes in seizure frequency

    Change is seizure frequency at longitudinal time points

    Time frame: baseline to up to one (1) year

  3. Evaluate changes in seizure severity

    Change is seizure severity at longitudinal time points

    Time frame: baseline to up to one (1) year

  4. Evaluate antiseizure medication

    Changes in the antiseizure medication (ASM) dosage

    Time frame: baseline to up to one (1) year

  5. Gather product deficiency and patient safety events

    Number and description of adverse events related to the device, user, RF ablation procedure, therapy, and others

    Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)

Other outcomes

  1. Evaluate seizure related hospitalizations

    Changes in seizure related emergency department visits and hospitalizations

    Time frame: baseline to up to one (1) year

  2. Evaluate device use

    Questionnaire to assess clinician satisfaction with the device

    Time frame: During the ablation procedure

  3. RF ablation parameters

    Collect RF ablation parameters (temperature and time) used for treatment

    Time frame: During RF ablation procedure

  4. RF ablation lesion characterization

    Measurement of RF ablation lesion size from MRI

    Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)

  5. Evaluate patient selection for RF ablation

    Tabulate RF ablation parameters, lesion size and seizure outcomes for each participant

    Time frame: From ablation through the completion of follow-up visits (approximately a one-year period)

  6. Evaluate health care resource utilization

    Location of the procedure: operating room or epilepsy monitoring unit

    Time frame: During the ablation procedure

  7. Evaluate health care resource utilization

    Personnel required for procedure

    Time frame: During the ablation procedure

  8. Evaluate health care resource utilization

    Total cost of index procedure and follow-up cate, if permissible

    Time frame: From enrollment through the completion of follow-up visits (approximately a one-year period)

07

Study locations

3 of 3 sites recruiting
  • Nicklaus Children's Hospital
    Miami, Florida 33155, United States
    Recruiting
  • Cooperman Barnabas Medical Center - 94 Old Short Hills Rd
    Livingston, New Jersey 07039, United States
    Recruiting
    • Robert E Gross, MD, PhD · Contactrg1246@rutgers.edu · 833-656-3876
    • Robert E Gross, MD, PhD · Principal investigator
  • Robert Wood Johnson University Hospital - 1 Robert Wood Johnson Pl
    New Brunswick, New Jersey 08901, United States
    Recruiting
    • Robert E Gross, MD, PhD · Contactrg1246@rwjms.rutgers.edu · 833-656-3876
    • Robert E Gross, MD, PhD · Principal investigator
08

References and documents

Publications

  • Freund BE, Vijayanarasimhan V, Safa A, Ekert J, Colella FE, Block C, Sabsevitz D, Perez-Vega C, Middlebrooks EH, Mirsattari SM, Byrne R, Tatum WO. Stereo-electroencephalography-guided radiofrequency thermocoagulation in patients with implanted neuromodulation devices: patient series. J Neurosurg Case Lessons. 2026 Aug 3;12(5):CASE26376. doi: 10.3171/CASE26376. Print 2026 Aug 3. PubMed 42546343 ↗
  • Zavala B, Kondylis E, Bulacio J, Chisholm J, Harasimchuk S, Rammo R, Bingaman W, Serletis D. Initial Clinical Experience with the First FDA-Approved sEEG-Guided Radiofrequency Ablation System Featuring Real-Time Temperature Monitoring: A Case Series. Stereotact Funct Neurosurg. 2026 Mar 5:1-8. doi: 10.1159/000551390. Online ahead of print. PubMed 41785222 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Jul 2028, 22 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 22, 2026
StartActual
Sep 18, 2026was Jul 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
3 sites added — first site in United States
Show 3 added (3 United States)
  • Nicklaus Children's Hospital · Miami, United States
  • Cooperman Barnabas Medical Center - 94 Old Short Hills Rd · Livingston, United States
  • Robert Wood Johnson University Hospital - 1 Robert Wood Johnson Pl · New Brunswick, United States
Oct 16, 2026
Start date
Jul 2026→Sep 18, 2026 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    3 sites added — first site in United States
    Show 3 added (3 United States)
    • Nicklaus Children's Hospital · Miami, United States
    • Cooperman Barnabas Medical Center - 94 Old Short Hills Rd · Livingston, United States
    • Robert Wood Johnson University Hospital - 1 Robert Wood Johnson Pl · New Brunswick, United States
    Start date Jul 2026→Sep 18, 2026 (now actual)
    + 3 other changes: verification date, responsible party and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07546253
Lead sponsor
NeuroOne Medical Technologies Corporation
Collaborators
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Sep 18, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Aura Kullmann, PhD
Contact
aurak@nmtc1.com
4123393027

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion